
| Pair Name | Cordycepin, Anti-CTLA-4 antibody | ||
| Phytochemical Name | Cordycepin (PubChem CID: 6303 ) | ||
| Anticancer drug Name | Anti-CTLA-4 antibody (PubChem CID: 101136468 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Cordycepin, Anti-CTLA-4 antibody | |||
| Disease Info | [ICD-11: 2B90.Z] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Immunomodulatory | |||
| In Vitro Model | MC-38 | Mouse colon adenocarcinoma | Mus musculus (Mouse) | CVCL_B288 |
| CT26 | Mouse colon adenocarcinoma | Mus musculus (Mouse) | CVCL_7254 | |
| In Vivo Model | 1×10⁶ MC38 cells in 100 µL of PBS and injected them subcutaneously (s.c.) into the right flank of C57BL/6J mice. In a similar manner, we injected 1×10⁶ CT26 cells, also suspended in 100 µL of PBS, s.c. into the right flank of Balb/c mice. | |||
| Result | Our current study successfully established a combination therapeutic strategy utilizing cordycepin and CTLA-4 blockade. This strategy demonstrated a significant synergistic effect against cancer, highlighting its importance in cancer treatment. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Cordycepin synergizes with CTLA-4 blockade to remodel the tumor microenvironment for enhanced cancer immunotherapy. Int Immunopharmacol. 2023 Nov;124(Pt A):110786. doi: 10.1016/j.intimp.2023.110786. | Click |